Corporate culture & governance

Innovation

The CHEMO Group is firmly committed to its objective of being at the forefront of scientific innovation. This is reflected in the considerable human and material investment made by the research and development departments (R&D) of its industrial plants.

Our research programs focus efforts in the field of women’s health, respiratory ailments and the developing of several innovative products based in our synthesis capabilities, the advice of key opinion leaders and targeting diseases for which current treatments do not match medical needs.

The innovative – mind is a strong characteristic of CHEMO. Our research, development and innovation departments are focused on the development of medicine for a variety of human applications.

Our professionals have excellent credentials and experience. They are equipped with the highest technology available for the development of new analytical methods and the monitoring of the stability of new products.

Also, the professional's responsible one of our pilot plant has to work in the field of research and development in the "pharmaceutical sciences" give particular emphasis to the development of galenic forms applicable both to "old active ingredients", where a modification of their galenic form could improve their therapeutic effectiveness, adapting their bio-availability, to the desired end.

At our disposal we have production teams that have the most advanced technology and suits all need for the development area, from test, laboratory tests pilot and industrials. The laboratories are equipped with the highest technology available for the development of new analytical methods and the monitoring of the stability of new products, for which purpose it has a "retention samples area" with controlled moisture and temperature where the product is kept in order to monitor its stability in real time.

At the present time we are working in multiple projects as new molecules or generic and generic products plus. The registries of new products are appearing in more than 40 countries.